| Abstrakt: |
A patent application has been submitted for approval by researchers Chiocca and Mineo. The application focuses on methods for predicting treatment outcomes to checkpoint inhibitors in cancer. The researchers highlight the need for more effective cancer treatments with predictable outcomes and fewer side effects. They propose a gene signature that includes the use of NEAT1 and/or HNRNPH1 as biomarkers to predict clinical response to immune checkpoint inhibitors in multiple cancer types. The methods involve obtaining a tumor sample, determining the expression levels of NEAT1 and/or HNRNPH1, comparing them to reference levels, and selecting appropriate immunotherapy treatments based on the results. [Extracted from the article] |
